SAN DIEGO , Nov. 21, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced that it has entered into a definitive agreement (the "Purchase Agreement") to acquire Extract Labs, Inc. ("Extract Labs"), a leading manufacturer and... Read More

SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended September 30, 2024 . Third Quarter 2024 and Recent Financial and Operating Highlights Generated revenue of... Read More

SAN DIEGO , Nov. 8, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the third quarter ended September 30, 2024 , before the stock market opens on Thursday, November 14, 2024.... Read More

Designed to elevate focus, mood, energy, and metabolism with clinically proven wellness ingredients Available in three variations - Clarity, Peace, and ReShape SAN DIEGO , Aug. 27, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company... Read More

SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2024 . Second Quarter 2024 and Recent Financial and Operating Highlights Generated revenue of... Read More

SAN DIEGO , Aug. 7, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the second quarter ended June 30, 2024 , before the stock market opens on Tuesday, August 13, 2024 . The... Read More

SAN DIEGO , May 14, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2024 . First Quarter 2024 and Recent Financial and Operating Highlights Generated revenue of... Read More

SAN DIEGO , May 13, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced that it has consummated its purchase of Elevated Softgels, LLC ("Elevated Softgels"), a leading manufacturer of encapsulated softgels and tinctures for... Read More

SAN DIEGO , May 8, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the first quarter ended March 31, 2024 , before the stock market opens on Tuesday, May 14, 2024 . The Company... Read More

SAN DIEGO , March 28, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2023 . Fiscal 2023, Fourth Quarter 2023 and Recent Financial and Operating... Read More

Pet Hip and Joint Health Chews and Pet Calming Care Chews improve the physical and emotional well-being of dogs SAN DIEGO , March 26, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven,... Read More

SAN DIEGO , March 21, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in nutraceuticals and plant-based foods, today announced that it will release financial results for the year and fourth quarter ended December 31, 2023 , before the stock market opens on Thursday, March 28, 2024 . The Company will hold a conference... Read More

SAN DIEGO , Dec. 12, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced that it has consummated its purchase of Cultured Foods , a leading manufacturer and distributor of alternative plant-based vegan foods. Cultured Foods... Read More

SAN DIEGO , Nov. 14, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended September 30, 2023 . Third Quarter 2023 and Recent Financial and Operating Highlights Increased revenue to... Read More

SAN DIEGO , Nov. 9, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the third quarter ended September 30, 2023 , before the stock market opens on Tuesday, November 14, 2023.... Read More

Premium sleep aid supports better sleep by combining melatonin and cannabinoids SAN DIEGO , Sept. 5, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced the launch of +PlusCBD™Reserve Collection Sleep Gummies as the brand... Read More

SAN DIEGO , Aug. 14, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2023 . Second Quarter 2023 and Recent Financial and Operating Highlights Generated revenue of... Read More

SAN DIEGO , Aug. 1, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the second quarter ended June 30, 2023 , before the stock market opens on Monday, August 14, 2023 . The... Read More

13th invitational event welcomes over 150 companies to over 800 attendees SAN DIEGO , June 1, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced that Joseph Dowling , its Chief Executive Officer, will present at the LD... Read More

SAN DIEGO , May 15, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2023 . First Quarter 2023 and Recent Financial and Operating Highlights Generated revenue of... Read More

SAN DIEGO , May 9, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the first quarter ended March 31, 2023 , before the stock market opens on Monday, May 15, 2023 . The Company... Read More

+PlusCBD™ Reserve Collection Extra Gummies provide easy-to-dose 5mg THC option SAN DIEGO , April 3, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients... Read More

SAN DIEGO , March 29, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2022 . Fiscal 2022, Fourth Quarter 2022 and Recent Financial and Operating... Read More

SAN DIEGO , March 24, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the year and fourth quarter ended December 31, 2022 , before the stock market opens on Wednesday, March... Read More

The Company is seeking strategic opportunities to advance the development of this program SAN DIEGO , March 23, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced that recently the Company received its formal Certificate... Read More

+PlusCBD™Daily Balance THC-Free products provide benefits of CBD without effects of THC SAN DIEGO , March 21, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural... Read More

SAN DIEGO , March 2, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, announced today that CV Sciences has received preliminary approval a proposed settlement of a derivative lawsuit pending in Nevada . The lawsuit alleged breach of... Read More

Smaller bottle allows for consumers flexibility at a more affordable price SAN DIEGO , Jan. 18, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI ) (the "Company", " CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients... Read More

SAN DIEGO , Nov. 14, 2022 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended September 30, 2022 . Third Quarter 2022 and Recent Financial and Operating Highlights Revenue of $3.8... Read More

SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the third quarter ended September 30, 2022 , before the stock market opens on Monday, November 14, 2022 . The Company will hold a conference call with the investment... Read More

CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, announced today that CV Sciences has received preliminary approval of the proposed settlement of six shareholder derivative lawsuits pending in Nevada and California . These lawsuits alleged breach of... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, announced today that CV Sciences extinguished its entire outstanding convertible debt. "We have retired all of our outstanding convertible debt which strengthens our balance sheet and helps us with our... Read More

PlusCBD™'s latest product leverages CBD and THC to target anxiety and stress CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced the launch of +PlusCBD™Reserve Collection Softgels to support stress relief and relaxation. The product will be... Read More

CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2022 . Second Quarter 2022 and Recent Financial and Operating Highlights Revenue of $4.1 million for second quarter of 2022, compared to... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Financial and Operating Highlights Revenue of $4.4 million for first quarter of 2022, compared to $4.8 million for the first quarter of 2021; Gross margin of 26.0%... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the first quarter ended March 31, 2022, before the stock market opens on Monday, May 16, 2022. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2021. Fiscal 2021 and Recent Financial and Operating Highlights Revenue of $20.0 million for fiscal year 2021, compared to $24.4 million for 2020; Gross margin of 43.0% for fiscal year 2021, compared... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2021, after the stock market closes on Thursday, March 31, 2022. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the addition of +PlusCBD Relief Softgels to its Wellness line of CBD products, joining our highly successful +PlusCBD Sleep & Calm Gummies. +PlusCBD... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the addition of +PlusCBD Relief Softgels to its Wellness line of CBD products, joining our highly successful +PlusCBD Sleep & Calm Gummies. +PlusCBD... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (“CBD”) products, today announced the launch of +PlusCBD™ Pain Relief topicals: four unique Over-the-Counter (“OTC”) products formulated to pinpoint sources of minor pain and aches... Read More

CV Sciences, Inc. (OTCQB: CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced a major new distribution agreement with GNC. Beginning in early 2022, consumers will be able to purchase the Company’s top selling ingestible products... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has appointed Haskell & White LLP ("H&W") as the Company's new independent registered public accounting firm. "Following a thorough selection process, the Company's Audit Committee has concluded that H&W is best positioned to meet the evolving... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has entered into a securities purchase agreement with an institutional investor, providing for the sale and issuance of convertible notes due 2022 in the aggregate original principal amount of $1.06 million. Upon our filing with the Securities... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended September 30, 2021. Third Quarter 2021 and Recent Financial and Operating Highlights Revenue of $5.1 million for third quarter of 2021, compared to $5.6 million for the third quarter of 2020; Gross margin of... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the third quarter ended September 30, 2021, before the stock market opens on Monday, November 15, 2021. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, applauds the California Legislature of its passage of AB 45 , which yesterday was signed into law by Governor Gavin Newson. This new law will explicitly permit the retail sale of products containing hemp-derived extracts and cannabinoids, such as CBD. “As a... Read More

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended June 30, 2021. Second Quarter 2021 and Recent Financial and Operating Highlights Revenue of $5.1 million for second quarter of 2021, compared to $5.4 million for... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the second quarter ended June 30, 2021, after the stock market closes on Thursday, August 12 , 2021. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m.... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it received NutraIngredients-USA ’s 2021 Product of the Year: Immune Support Award for its CV™ Defense product. Focusing on true innovation, long-term market success and cutting-edge research, the NutraIngredients-USA Awards honor the best and... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced progress toward its goal of developing and commercializing a CBD-based pharmaceutical to treat nicotine addiction in smokeless tobacco users. The Company, in collaboration with researchers from the University of California, San Diego (“UC San Diego”), published a... Read More

CV Sciences, Inc . (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2021. First Quarter 2021 and Recent Operating Highlights Revenue of $4.8 million for first quarter of 2021, compared to $8.3 million for the first quarter of 2020; Gross margin of 48.7% for first... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced the launch of PlusCBD™ Calm and Sleep: two flavorful gummies that support healthy stress responses and sleep cycles for people getting back to their normal... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the first quarter ended March 31, 2021, after the stock market closes on Thursday, May 13, 2021. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m.... Read More

CV Sciences, Inc . (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced an ongoing partnership with Alkemist Labs, an established leader in botanical plant testing, to collaborate with the National Institute of Standards and Technology (“NIST”) on efforts to help cannabis testing labs demonstrate and improve measurement capabilities... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2020. Fiscal 2020 and Recent Operating Highlights Revenue of $24.4 million for fiscal year 2020; Gross margin of 45.1% for fiscal year 2020; Maintained total cash balance of $4.5 million at year end;... Read More

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the fiscal year and fourth quarter ended December 31, 2020, after the stock market closes on Thursday, March 18, 2021. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific... Read More